Stallergenes Greer Expands into the Nordic Region with the Establishment of an Affiliate Dedicated to the Danish, Norwegian and Swedish Markets

24.10.2024 11:09:00 CEST | Business Wire | Press Release

Stallergenes Greer, a global leader in allergen immunotherapy (AIT), is pleased to announce its expansion into the Nordic region with the establishment of an affiliate dedicated to the Danish, Norwegian, and Swedish markets. Stallergenes Greer Danmark ApS provides the medical community and patients with a fully registered portfolio of sublingual tablet treatments for grass pollen and house dust mite-induced allergic rhinitis.

In Europe, allergic rhinitis affects 1 in 5 people (19% prevalence)¹, a proportion that has been increasing over the past decades. It is mostly caused by aeroallergens such as pollen or house dust mites, triggering nasal and ocular symptoms that can impair daily life and potentially progress to allergic asthma—a chronic and debilitating condition affecting 15% to 38% of patients with allergic rhinitis².

“We are delighted to enter the Nordic region and contribute to improving the quality of life for patients with grass pollen and house dust mite allergies. With the establishment of Stallergenes Greer Danmark ApS, allergy sufferers and physicians in Denmark, Norway, and Sweden can rely on Stallergenes Greer’s dedication to providing effective, high-quality, and clinically proven allergen immunotherapy treatments”, says Brice Chouquet, Country Manager for the Nordic region. Finland will follow in 2025.

The expansion of Stallergenes Greer’s geographic footprint into the Nordic region is a testament to the Group’s commitment to providing patients and healthcare professionals worldwide with comprehensive allergy care. With nearly 120 years of expertise in allergy and allergen immunotherapy (AIT), Stallergenes Greer has an extensive global presence and significant capacity for allergen and finished AIT product manufacturing. Building on its longstanding expertise in allergen immunotherapy, Stallergenes Greer’s innovative treatments are designed to address the specific needs of allergy sufferers.

ABOUT STALLERGENES GREER DANMARK APS

Stallergenes Greer Danmark ApS is a subsidiary of Stallergenes Greer AG, a global healthcare company based in Baar, Switzerland, specializing in the diagnosis and treatment of respiratory, food, and venom allergies through the development and commercialization of allergen immunotherapy products and services. Stallergenes Greer International AG is the parent company of Greer Laboratories, Inc. (registered in the United States) and Stallergenes SAS (registered in France). For more information, visit www.stallergenesgreer.com.

Savouré et al., Worldwide prevalence of rhinitis in adults: A review of definitions and temporal evolution, Clin and Translat Allergy 2022 Vol. 12 Issue 3, article e12130.
Brozek et al., Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines-2016, revision J Allergy Clin Immunol 2017 Vol. 140 Issue 4 Pages 950-958.

View source version on businesswire.com: https://www.businesswire.com/news/home/20241024900607/en/

Contacts

Stallergenes Greer Danmark ApS
Business Center - Rådhuspladsen 16 - 1550 København - Danmark
CVR 44474492
Email: hello.nordics@stallergenesgreer.com

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Incyte’s Pivotal frontMIND Trial Showed Tafasitamab (Monjuvi ® /Minjuvi ® ) Combination Significantly Prolonged Progression-free Survival, Reducing the Risk of Disease Progression or Death by 25% in Patients with Previously Untreated, High-risk DLBCL30.5.2026 14:00:00 CEST | Press Release

Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®), a humanized Fc-modified cytolytic CD19-targeting monoclonal antibody, and lenalidomide added to R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone; Tafa-Len-R-CHOP) versus R-CHOP alone as a first-line treatment for adults with previously untreated diffuse large B-cell lymphoma (DLBCL) or high-grade B-cell lymphoma (HGBL). Eligible patients had an International Prognostic Index (IPI) score of 3-5, or, for patients ≤60 years of age, an age-adjusted IPI (aaIPI) of 2-3. The oral presentation of these data is taking place at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting being held May 29 – June 2, 2026, in Chicago (Abstract #LBA7000. Session: Oral Abstract Session – Hematologic Malignancies – Lymphoma and Chronic Lymphocytic Leukemia. May 30, 4:00 – 7:00 p.m. ET [3:00 – 6:00 p.m.

Fortegra Completes Acquisition by DB Insurance29.5.2026 22:30:00 CEST | Press Release

The Fortegra Group, Inc. ("Fortegra"), a global specialty insurance company, today announced the completion of its acquisition by DB Insurance Co., Ltd. ("DB"), one of Korea's leading property and casualty insurers. The transaction, announced on September 26, 2025, received all required regulatory and stockholder approvals. Fortegra will operate independently, maintaining its existing leadership team, distribution relationships, and underwriting discipline. Agents, distribution partners, and customers will continue to experience the service excellence that has defined the Fortegra experience. Richard Kahlbaugh, Chairman and CEO of Fortegra, said: "Every company eventually changes ownership. That is the nature of business. The closing of this acquisition is a starting point. As part of DB Insurance, Fortegra is positioned to expand our business geographically, enhance our capabilities and deepen our market presence in the US, Europe, the United Kingdom and Asia. Together, DB Insurance a

SINOVAC Receives Nasdaq Notification Regarding Late Filing of 2025 Annual Report29.5.2026 22:01:00 CEST | Press Release

Sinovac Biotech Ltd. (Nasdaq: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today announced that it received a notification letter dated May 20, 2026 (the “Notification Letter”), from Nasdaq Listing Qualifications (“Nasdaq”) stating that as of May 8, 2026, the Company had regained compliance with the periodic filing and interim financial requirements in Nasdaq Listing Rules 5250(c)(1) (the “Periodic Filing Rule”) and 5250(c)(2), as required by the Panel’s decision dated January 21, 2026. As previously disclosed on January 22, 2026, under the Panel’s decision, SINOVAC was required to, on or before May 11, 2026, demonstrate compliance with such Nasdaq Listing Rules by completing filings of its annual report for the year ended December 31, 2024, on Form 20-F and an interim balance sheet and income statement as of the end of its second quarter of 2025 on Form 6-K. The Company timely completed such filings as required by the Panel’s decision.

From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press Release

NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under 20 minutes, saving hundreds of hours of engineer time, shrinking MTTR by more than 95%. A global telecommunications firm found NetBrain's context-grounded agents outperformed a stand-alone frontier LLM on a persistent firewall

Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press Release

Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consistent approach to protecting our innovation and our customers,” said Justin Ferguson, SVP and general counsel at Adtran. “We take all claims seriously, but we will not hesitate to defend ourselves when assertions lack merit. Situations like this place unnecessary strain on technology providers and divert resources from advancing networks and services. By advancing our counterclaim

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom